Fragment-Based Drug Discovery
1st Edition
Published on 17. June 2015
314 pages
978-1-78262-565-0 (ISBN)
Description
Fragment-based drug discovery is a rapidly evolving area of research, which has recently seen new applications in areas such as epigenetics, GPCRs and the identification of novel allosteric binding pockets. The first fragment-derived drug was recently approved for the treatment of melanoma. It is hoped that this approval is just the beginning of the many drugs yet to be discovered using this fascinating technique.
This book is written from a Chemist's perspective and comprehensively assesses the impact of fragment-based drug discovery on a wide variety of areas of medicinal chemistry. It will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in novel drug discovery techniques.
This book is written from a Chemist's perspective and comprehensively assesses the impact of fragment-based drug discovery on a wide variety of areas of medicinal chemistry. It will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in novel drug discovery techniques.
More details
Series
Language
English
Place of publication
Cambridge
United Kingdom
Target group
Professional and scholarly
Product notice
Reflowable
ISBN-13
978-1-78262-565-0 (9781782625650)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Steven Howard | Chris Abell
Fragment-Based Drug Discovery
Book
07/2015
Royal Society of Chemistry
€217.50
Article not available at the moment
Steven Howard | Chris Abell
Fragment-Based Drug Discovery
E-Book
06/2015
1st Edition
Royal Society of Chemistry
€233.99
Available for download
Persons
Content
Different flavours of Fragments;
Advances in SPR Technology;
Applications of NMR in Fragment-Based Drug Discovery;
Issues around Fragments as an Approach, including a Computational/in silico Perspectives on Fragment-Based Drug Discovery;
Fragment-Based Drug Discovery of Kinase Inhibitors;
Fragment-Based Discovery of Antibacterials;
Strategies for Fragment-Based Lead Generation;
Fragment-Based Approaches to Epigenetic Targets;
Application of Fragment-Based Drug Discovery to GPCRs;
Fragment-Based Drug Discovery applied to Protein-Protein Interactions;
Probing Difficult Targets
Advances in SPR Technology;
Applications of NMR in Fragment-Based Drug Discovery;
Issues around Fragments as an Approach, including a Computational/in silico Perspectives on Fragment-Based Drug Discovery;
Fragment-Based Drug Discovery of Kinase Inhibitors;
Fragment-Based Discovery of Antibacterials;
Strategies for Fragment-Based Lead Generation;
Fragment-Based Approaches to Epigenetic Targets;
Application of Fragment-Based Drug Discovery to GPCRs;
Fragment-Based Drug Discovery applied to Protein-Protein Interactions;
Probing Difficult Targets
